TY - JOUR
T1 - Slow-growing lung cancer as an emerging entity
T2 - From screening to clinical management
AU - Infante, Maurizio
AU - Berghmans, Thierry
AU - Heuvelmans, Marjolein A.
AU - Hillerdal, Gunnar
AU - Oudkerk, Matthijs
PY - 2013/12/1
Y1 - 2013/12/1
N2 - The current paradigm is that untreated lung cancer is invariably and rapidly fatal, therefore the medical community normally dismisses the idea that a patient could live with such a disease for years without any therapy. Yet evidence from lung cancer screening research and from recent clinical series suggests that, although rarely recognised in routine practice, slow-growing lung cancers do exist and are more common than previously thought. Here, current evidence is reviewed and clinical cases are illustrated to show that slow-growing lung cancer is a real clinical entity, and the reasons why management protocols developed in the screening setting may also be useful in clinical practice are discussed. Features suggesting that a lung cancer may be slow-growing are described and appraised, areas of uncertainty are examined, modern management options for early-stage disease are evaluated and the influence that all this knowledge might have on our clinical decision-making is weighed. Further research directed at developing appropriate guidelines for these peculiar but increasingly common patients is warranted.
AB - The current paradigm is that untreated lung cancer is invariably and rapidly fatal, therefore the medical community normally dismisses the idea that a patient could live with such a disease for years without any therapy. Yet evidence from lung cancer screening research and from recent clinical series suggests that, although rarely recognised in routine practice, slow-growing lung cancers do exist and are more common than previously thought. Here, current evidence is reviewed and clinical cases are illustrated to show that slow-growing lung cancer is a real clinical entity, and the reasons why management protocols developed in the screening setting may also be useful in clinical practice are discussed. Features suggesting that a lung cancer may be slow-growing are described and appraised, areas of uncertainty are examined, modern management options for early-stage disease are evaluated and the influence that all this knowledge might have on our clinical decision-making is weighed. Further research directed at developing appropriate guidelines for these peculiar but increasingly common patients is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84887345872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887345872&partnerID=8YFLogxK
U2 - 10.1183/09031936.00186212
DO - 10.1183/09031936.00186212
M3 - Article
C2 - 23682109
AN - SCOPUS:84887345872
SN - 0903-1936
VL - 42
SP - 1706
EP - 1722
JO - European Journal of Respiratory Diseases
JF - European Journal of Respiratory Diseases
IS - 6
ER -